Chronic myeloid leukemia (CML) patients treated with nilotinib(Drug information on nilotinib) had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib(Drug information on imatinib), and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease, according to results from the phase III ENESTnd trial. http://www.cancernet...e/10165/2137550
Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib
Posted 16 May 2013 - 04:26 PM
Although useful information there is no way to know if mutations arose during Tasigna treatment which were dealt with by the Tasigna. Since Gleevec cannot overcome some of the main mutations Tasigna can overcome, the mutations will show up for the Gleevec patients. But Tasigna patients probably develop the mutations at a similar rate but they are disposed of before testing can see them since the testing sensitivity is limited.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users